Redhill Biopharma - ADR

NASDAQ:RDHL  
4.87
-0.09 (-1.82%)
Earnings Announcements

Redhill Biopharma Provides Q4 Revenue Of $21.5 mln

Published: 03/18/2021 11:18 GMT
Redhill Biopharma - ADR (RDHL) - Redhill Biopharma Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights.
Q4 Revenue $21.5 Million.
Planned Commercial Operational Breakeven by End of 2021.
Revenue is expected to be $24.51 Million
Adjusted EPS is expected to be -$0.47

Next Quarter Revenue Guidance is expected to be $28.62 Million
Next Quarter EPS Guidance is expected to be -$0.34

More details on our Analysts Page.